Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial entities : Moleculin biotech, inc. save search
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 5.18%
H: 0.0%
C: -12.5%
mb-106 positive aml trial
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual Meeting
Published: 2023-12-11 (Crawled : 14:30) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -2.25%
H: 3.98%
C: -5.95%
positive aml meeting trial
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
Published: 2023-11-13 (Crawled : 13:00) - prnewswire.com
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 10.65%
H: 8.02%
C: -3.56%
mb-106 lung mb-107 positive aml trial response
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
Published: 2023-11-06 (Crawled : 13:30) - prnewswire.com
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 0.67%
H: 16.45%
C: 14.21%
lung disease positive treatment trial
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2023-10-02 (Crawled : 13:00) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 2.46%
H: 0.0%
C: -0.23%
treatment leukemia trial
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)
Published: 2023-09-21 (Crawled : 13:30) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -0.03%
H: 9.98%
C: 9.98%
mb107 lung treatment trial
Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Published: 2023-07-13 (Crawled : 14:00) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 6.47%
H: 27.69%
C: 10.57%
publication treatment leukemia trial
Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2023-05-02 (Crawled : 13:20) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -0.65%
H: 7.89%
C: 5.26%
treatment leukemia trial
Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials
Published: 2023-03-22 (Crawled : 22:00) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: -4.63%
expected update trials aml trial
Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2023-03-01 (Crawled : 14:00) - prnewswire.com
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -0.1%
H: 3.41%
C: -0.73%
treatment leukemia trial
Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Published: 2023-02-13 (Crawled : 13:20) - prnewswire.com
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 5.82%
H: 4.84%
C: -4.84%
treatment topline leukemia trial phase 1
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2022-12-21 (Crawled : 14:00) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -1.52%
H: 0.18%
C: -3.85%
treatment leukemia trial approval acute myeloid leukemia aml phase 1
Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2022-12-15 (Crawled : 20:00) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 6.67%
H: 4.17%
C: -4.17%
treatment leukemia trial response acute myeloid leukemia aml
Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Published: 2022-10-14 (Crawled : 13:00) - prnewswire.com
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -3.0%
H: 6.19%
C: 3.09%
wp1122 trial update
Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Published: 2022-08-19 (Crawled : 13:00) - prnewswire.com
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 0.57%
H: 0.56%
C: -5.08%
wp1122 trial
Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -2.96%
H: 4.27%
C: 3.66%
treatment trial phase 2 soft tissue phase 2b
Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Published: 2022-07-08 (Crawled : 13:00) - prnewswire.com
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -5.92%
H: 10.06%
C: 6.29%
wp1122 trial phase 1
Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Published: 2022-06-16 (Crawled : 13:20) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: -2.16%
H: 2.21%
C: -2.21%
wp1122 trial phase 1
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published: 2022-05-26 (Crawled : 13:20) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 2.22%
H: 5.8%
C: 4.35%
wp1122 covid-19 treatment trial phase 1
Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published: 2022-05-10 (Crawled : 13:00) - biospace.com/
MBRX | $4.59 7.24% 6.75% 50K
|
Health Technology
|
| O: 2.64%
H: 4.39%
C: -2.94%
wp1122 covid-19 treatment trial approval phase 1
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.